ZP
BPMC

Zimmer Partners’s Blueprint Medicines BPMC Stock Holding History

Zimmer Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,620
Closed -$851K – 166
2025
Q1 		$851K Sell
9,620
-24,030
-71% -$2.34M 0.02% 164
2024
Q4 		$2.93M Buy
33,650
+12,550
+59% +$1.15M 0.05% 124
2024
Q3 		$1.95M Buy
+21,100
New +$2.1M 0.04% 132
2023
Q3 		– Sell
-28,400
Closed -$1.79M – 127
2023
Q2 		$1.79M Buy
+28,400
New +$1.54M 0.04% 95

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Zimmer Partners's BPMC Position: Q2 2025 in Review

Zimmer Partners sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 9,620 shares — an estimated $851K sold.

Zimmer Partners first reported a position in BPMC in Q2 2023 and held it in 4 quarters. The position peaked at $2.93M in Q4 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Zimmer Partners reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Zimmer Partners sold 9,620 Blueprint Medicines shares in Q2 2025, an estimated $851K.
  • Zimmer Partners first reported a position in Blueprint Medicines in Q2 2023 and held it in 4 quarters.
  • Zimmer Partners's Blueprint Medicines position peaked at $2.93M in Q4 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Zimmer Partners's 13F filing for Q2 2025, filed 14 Aug 2025.